NDAORALCAPSULE
Approved
Feb 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TETREX is a tetracycline phosphate complex oral capsule, a broad-spectrum antibiotic approved in 1957. It is used to treat bacterial infections across multiple indications. The drug works by inhibiting bacterial protein synthesis through ribosomal binding.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%); teams are likely focused on managed decline or niche positioning strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TETREX offers limited growth opportunities due to LOE approaching and minimal linked job openings. Career development is better suited for professionals interested in lifecycle management, cost optimization, and transition planning rather than launch or expansion roles.
Brand ManagerSales Representative
Worked on TETREX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.